Skip to main content
Premium Trial:

Request an Annual Quote

BGI Extends Offer to Acquire Complete Genomics

NEW YORK (GenomeWeb News) – BGI-Shenzhen today said that it has extended its offer to acquire Complete Genomics for $3.15 per share.

The offer, with a total deal value of nearly $118 million, was scheduled to expire at midnight tonight, New York City time. It has now been extended to midnight on Wednesday, Nov. 21.

According to BGI, as of the close of business yesterday, approximately 6,731,897 shares had been validly tendered and not withdrawn from the offer. Complete Genomics has roughly 34.3 million total shares outstanding.

BGI launched its offer to merge with Complete Genomics in mid-September. Since the deal was announced, a handful of shareholder lawsuits have been filed against Complete Genomics, its board of directors, and executives seeking to block the deal.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.